405 results on '"Sharyn D. Baker"'
Search Results
2. DNA methyltransferase inhibitor exposure–response: Challenges and opportunities
3. Increased renal elimination of endogenous and synthetic pyrimidine nucleosides in concentrative nucleoside transporter 1 deficient mice
4. Targeting a xenobiotic transporter to ameliorate vincristine-induced sensory neuropathy
5. Author Correction: Increased renal elimination of endogenous and synthetic pyrimidine nucleosides in concentrative nucleoside transporter 1 deficient mice
6. DNA Methylation‐Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia
7. A kinome-wide screen identifies a CDKL5-SOX9 regulatory axis in epithelial cell death and kidney injury
8. Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia
9. Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT3‐ITD AML
10. TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with TP53 Mutation/Deletion
11. Itraconazole-Induced Increases in Gilteritinib Exposure Are Mediated by CYP3A and OATP1B
12. A Metabolomics Approach for Predicting OATP1B-Type Transporter-Mediated Drug–Drug Interaction Liabilities
13. Interaction Between Sex and Organic Anion‐Transporting Polypeptide 1b2 on the Pharmacokinetics of Regorafenib and Its Metabolites Regorafenib‐N‐Oxide and Regorafenib‐Glucuronide in Mice
14. A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML
15. Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms
16. TP-0903 is active in models of drug-resistant acute myeloid leukemia
17. Interaction of Antifungal Drugs with CYP3A- and OATP1B-Mediated Venetoclax Elimination
18. Role of equilibrative nucleoside transporter 1 (ENT1) in the disposition of cytarabine in mice
19. Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia
20. A phosphotyrosine switch regulates organic cation transporters
21. Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors
22. Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib
23. Hypoxia Reporter Element Assay
24. DPYD Testing: Time to Put Patient Safety First
25. Contribution of CNT1 and CNT3 to the intestinal transport and pharmacokinetics of decitabine
26. Characterization of microenvironmental-mediated gilteritinib resistance in Acute Myeloid Leukemia using a Bmx knockout mouse model
27. Supplementary Excel Tables from Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators
28. Supplementary Tables and Figures from Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators
29. Data from Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators
30. Supplementary Figure 5 from Inhibition of OCTN2-Mediated Transport of Carnitine by Etoposide
31. Supplementary Figure 1 from Inhibition of OCTN2-Mediated Transport of Carnitine by Etoposide
32. Supplementary Figure 3 from Inhibition of OCTN2-Mediated Transport of Carnitine by Etoposide
33. Supplementary Figure Legends 1-5 from Inhibition of OCTN2-Mediated Transport of Carnitine by Etoposide
34. Data from Inhibition of OCTN2-Mediated Transport of Carnitine by Etoposide
35. Supplementary Figure 2 from Inhibition of OCTN2-Mediated Transport of Carnitine by Etoposide
36. Supplementary Figure 4 from Inhibition of OCTN2-Mediated Transport of Carnitine by Etoposide
37. Supplementary Table 4 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
38. Supplementary Figure 6 from Contribution of Abcc4-Mediated Gastric Transport to the Absorption and Efficacy of Dasatinib
39. Supplementary Methods from Ontogeny and Sorafenib Metabolism
40. Data from Interaction of the Multikinase Inhibitors Sorafenib and Sunitinib with Solute Carriers and ATP-Binding Cassette Transporters
41. CCR Translation for This Article from Influence of Smoking on the Pharmacokinetics and Toxicity Profiles of Taxane Therapy
42. Supplementary Figure 3 from Contribution of Abcc4-Mediated Gastric Transport to the Absorption and Efficacy of Dasatinib
43. Supplementary Figure 6 from Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide
44. Data from Cellular Uptake of Imatinib into Leukemic Cells Is Independent of Human Organic Cation Transporter 1 (OCT1)
45. Supplementary Methods from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
46. Supplementary Figures and Tables from OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues
47. Supplementary Table S1 from Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia
48. Data from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
49. Supplementary Figure from Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication
50. Supplementary Figure 3 from Ontogeny and Sorafenib Metabolism
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.